For its first 15 years, Nexus Pharmaceuticals has relied on contractors to manufacture the sterile injectable meds it develops. Figuring it is high time to do that itself, the Chicago-area company has launched a $250 million project that will give it that
Nexus Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial.....